Sol-Gel Technologies Ltd. announced that it has entered into a second development and licensing agreement with a leading U.S. pharmaceutical company for the development and commercialization in the U.S. and Canada of a major dermatologic drug. Under the terms of the new agreement, Sol-Gel will receive $27 million, comprised of...
Read more